

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/802,273
Filing Date	03/17/04
First Named Inventor	Rodriguez
Art Unit	1614
Examiner Name	Leslie A. Royds
Attorney Docket Number	31162B

Sheet 1 of 8

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
LAR		US- 3,957,982	05-18-1976	Lachnit-Fixson et al.	
LAR		US- 3,969,502	07-13-1976	Lachnit-Fixson	
LAR		US- 4,390,531	06-28-1983	Edgren	
LAR		US- 4,530,839	07-23-1985	Pasquale	
LAR		US- 4,544,554	10-01-1985	Pasquale	
LAR		US- 4,616,006	10-07-1986	Pasquale	
LAR		US- 4,621,079	11-04-1986	Lachnit-Fixson et al.	
LAR		US- 4,628,051	12-09-1986	Pasquale	
LAR		US- 4,760,053	07-26-1988	Labrie	
LAR		US- 4,817,819	04-04-1989	Kelly	
LAR		US- 4,833,125	05-23-1989	Neer	
LAR		US- 4,855,305	08-08-1989	Cohen	
LAR		US- 4,906,169	03-06-1990	Chien	
LAR		US- 4,921,843	05-01-1990	Pasquale	
LAR		US- 4,962,098	10-09-1990	Boissonneault	
LAR		US- 5,108,995	04-28-1992	Casper	
LAR		US- 5,256,421	10-26-1993	Casper	
LAR		US- 5,262,408	11-16-1993	Bergink	
LAR		US- 5,280,023	01-18-1994	Ehrlich et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
LAR		EP 0 253 607 A1	01-20-1988	Upton		
		EP 0 253 607 B1	01-20-1988	Upton		
LAR		EP 0 628 312 B1	12-14-1994	Wablat		
LAR		WO 95/26730 A1	10-12-1995	Schering		
LAR		WO 97/11680	04-03-1997	Elliesen		
LAR		WO 98/10771 A1	03-19-1998	Rodriguez		

Examiner  
SignatureDate  
Considered

11 OCTOBER 2006

\*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet 2

of 8

**Complete if Known**

Application Number	10/802,273
--------------------	------------

Filing Date	03/17/04
-------------	----------

First Named Inventor	Rodriguez
----------------------	-----------

Art Unit	1614
----------	------

Examiner Name	Leslie A. Royds
---------------	-----------------

Attorney Docket Number	31162B
------------------------	--------

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
LAR		US- 5,314,694	05-24-1994	Gale et al.	
LAR		US- 5,382,573	01-17-1995	Casper	
WAR		US- 5,416,091	05-16-1995	King	
LAR		US- 5,418,228	05-23-1995	Bennink	
LAR		US- 5,422,119	06-06-1995	Casper	
LAR		US- 5,461,041	10-24-1995	Bergink et al.	
LAR		US- 5,468,736	11-21-1995	Hodgen	
LAR		US- 5,552,394	09-03-1996	Hodgen	
LAR		US- 5,583,129	12-10-1996	Spona et al.	
LAR		US- 5,595,970	01-21-1997	Garfield et al.	
LAR		US- 5,620,705	04-15-1997	Dong et al.	
LAR		US- 5,633,011	05-27-1997	Dong et al.	
LAR		US- 5,747,480	05-05-1998	Gast	
LAR		US- 5,780,497	07-14-1998	Miller et al.	
LAR		US- 5,842,476	12-01-1998	Wright et al.	
LAR		US- 5,855,906	01-05-1999	McClay	
LAR		US- 5,858,405	01-12-1999	Gast	
LAR		US- 5,888,543	03-30-1999	Gast	
LAR		US- 5,891,868	04-06-1999	Cummings et al.	

[illegible]

**Examiner  
Signature**

Date  
Considered

11 OCTOBER 2006

\*EXAMINER: Initial reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**


**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number	10/802,273
		Filing Date	03/17/04
		First Named Inventor	Rodriguez
		Art Unit	1614
		Examiner Name	Leslie A. Royds
Sheet 3 of 8	Attorney Docket Number	31162B	

U. S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
LAR		US- 5,898,038	04-27-1999	Yallampalli et al.	
LAR		US- 5,922,349	07-13-1999	Ellesen et al.	
LAR		US- 6,028,064	02-22-2000	Rodriguez et al.	
LAR		US- 6,034,074	03-07-2000	Rodriguez et al.	
LAR		US- 6,310,054	10-30-2001	Rodriguez et al.	
LAR		US- 6,319,911	11-20-2001	Rodriguez et al.	
LAR		US- 6,407,082	06-18-2002	Rodriguez et al.	
LAR		US- 6,444,658	09-03-2002	Rodriguez et al.	
LAR		US- 6,511,970	01-28-2003	Rodriguez et al.	
LAR		US- 6,765,002	07-20-2004	Rodriguez et al.	
LAR		US- 6,977,250	12-20-2005	Rodriguez et al.	
LAR		US- 7,053,074	05-30-06	Rodriguez et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

Examiner Signature		Date Considered	11 OCTOBER 2006
--------------------	---	-----------------	-----------------

\*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/802,273
		Filing Date	03/17/04
		First Named Inventor	Rodriguez
		Art Unit	1614
		Examiner Name	Leslie A. Royds
Sheet 4	of 8	Attorney Docket Number	31162B

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LAAR		ARCHER, et al., A new low-dose monophasic combination oral contraceptive (Alesse) with levonorgestrel 100 mg and Ethinyl Estradiol 20 mg, Contraception, (1997) 55:139-144	
HAAR		BAST, et al., Ovarian Cancer, Harrison's Principles of Internal Medicine, 1994, Chapter 321, 13th Ed., Isselbacher et al., (Eds.) pp. 1853-1858, McGraw-Hill, New York	
HAAR		BU, et al., Progesterone Induces Apoptosis and Up-Regulation of p53 Expression in Human Ovarian Carcinoma Cell Lines, Amer. Cancer Society, 1997, 79:1944-1950, China	
LAAR		CASAGRANDE, et al., "Incessant Ovulation" and Ovarian Cancer, The Lancet, July 28, 1979, pp. 170-172, Los Angeles, California	
MAAR		EVANGELOU, et al., Down-regulation of Transforming Growth Factor B receptors by androgen in ovarian cancer cells, Cancer Research, 2000, 60:929-935	
LAAR		FRANSESCHI, et al., Pooled Analysis of 3 European Case-Control Studies of Epithelial Ovarian Cancer: III. Oral Contraceptive Use, Int. J. Cancer, 1991, 49:61-65, Wiley-Liss	
LAAR		GREENE, et al., The Epidemiology of Ovarian Cancer, Seminars in Oncology, September 1984, pp. 209-225, Vol. 11, No. 3, USA	
LAAR		GRIMES, et al., Primary Prevention of Gynecologic Cancers, Am. J. Obstet. Gynecol., January 1995, pp. 227-235, San Francisco, California	
LAAR		GROSS, et al., The Estimated Effect of Oral Contraceptive Use on the Cumulative Risk of Epithelial Ovarian Cancer, OCs and Ovarian Cancer, 1994 pp. 419-424, Vol. 83, No. 3 USA	
LAAR		HAMMOND, Climacteric, Danforth's Obstetrics and Gynecology, 1994, pp. 771-790, Chapter 42, 7th Ed., Philadelphia	

Examiner Signature		Date Considered	11 OCTOBER 2006
--------------------	---	-----------------	-----------------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/802,273
		Filing Date	03/17/04
		First Named Inventor	Rodriguez
		Art Unit	1614
		Examiner Name	Leslie A. Royds
Sheet 5 of 8	Attorney Docket Number	31162B	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LAL		HICKEY, et al., Metabolic and Endocrinologic Effects of Steroidal Contaception, J. Sciarra Editor, 1996, pp. 1-14, Vol. 6, Chapter 24, Lippincott, Philadelphia	
LAL		JORDAN, The Estrogenic Activity of Synthetic Progestins Used in Oral Contraceptives, Cancer, 1993, Vol. 71, No. 4, pp. 1501-1505	
LAL		LEE, The Reduction in Risk of Ovarian Cancer Associated with Oral Contraceptive Use, 1987, New Engl. J. Med., 316:650-655	
LAL		LEFKOWITZ, et al., Sunlight, Vitamin D, and Ovarian Cancer Mortality Rates in US Women, International Journal of Epidemiology, 1994, pp. 1133-1136, Vol 23, No 6, Great Britian	
LAL		LIANG, et al., Risk of Breast, Uterine Corpus, and Ovarian Cancer in Women Receiving Medroxyprogesterone Injections, JAMA, 1983, pp. 2909-2912, Vol. 249, No. 21, USA	
LAL		LINGEMAN, Etiology of Cancer of the Human Ovary: A Review, The Journal of the National Cancer Institute, December 1974, pp. 1603-1618, Vol. 53, No. 6	
LAL		LOCKER, et al. Hormonal Therapy of breast cancer, Cancer Treatment Reviews, 1998, Vol. 24, pp. 221-240, W.B. Saunders Company Ltd.	
LAL		LOCKSHIN, et al., The Biology of Cell Death and Its Relationship to Aging, Cellular Aging and Cell Death, 1996, pp. 167-180, Wiley-Liss Inc.	
LAL		LOWE, et al., p53-Dependent Apoptosis in Tumor Progression and in Cancer Therapy, Cellular Aging and Cell Death, 1996, pp. 209-234, Wiley-Liss, Inc.	
LAL		LUNDGREN, et al., Progestins in Breast Cancer treatment, ACTA Oncologica, 1992, Vol. 31, No. 7, pp. 709-722, Trondheim, Norway.	

Examiner Signature		Date Considered	11 October 2006
--------------------	---	-----------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/802,273
		Filing Date	03/17/04
		First Named Inventor	Rodriguez
		Art Unit	1614
		Examiner Name	Leslie A. Royds
Sheet 6	of 8	Attorney Docket Number	31162B

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LAR		MAGOFFIN, et al., Estradiol-17B, insulin like growth factor-1, and lutenizing hormone inhibit secretion of transforming growth factor B by rat ovarian theca-interstitial	
↓		(continued from above) cells, Biology of Reproduction, 1995, 53, pp. 627-635	
LAR		MUSS, et al., High-dose progestin therapy for metastatic breast cancer, Annals of Oncology, 1992, pp. S15-S20, Vol. 3, Netherlands	
LAR		MUSS, Tamoxifen Versus High-Dose oral medroxyprogesterone Acetate as intital endocrine therapy for patients with metastatic breast cancer: A Peidmont,	
↓		(continued from above) Oncology Associate Study, Journal of Clinical Oncology, 1994, pp. 1630-1638, Vol. 12, No. 8	
LAR		MUTCH, et al., Biology of Epithelial Ovarian Cancer, Clinical Obstetrics and Gynecology, 1994, pp. 406-422, Vol. 37, No. 2, L.B. Lippincott Co.	
LAR		PFLEIDERER, The Problems of Prophylactic Chemotherapy, Second-look Surgery, and Maintenance of Remission in Therapy of Ovarian Cancer, Geburtshilfe und Frauenheikunde,	
↓		(continued from above) 1976, pp. 132-139, Vol. 36, Germany	
NAK		RAVIN, et al., Preformulation, Remington's Pharmaceutical Sciences, 1990, pp. 1435-1712, Chapters 75-92, Mack Publishing Co., Easton, PA	
LAR		RODRIGUEZ, et al., Estrogen Replacement Therapy and Fatal Ovarian Cancer, American Journal of Epidemiology, 1995, pp. 828-835, Vol. 141, No. 9, USA	

Examiner Signature		Date Considered	11 October 2006
--------------------	---	-----------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 36 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/802,273
		Filing Date	03/17/04
		First Named Inventor	Rodriguez
		Art Unit	1614
		Examiner Name	Leslie A. Royds
Sheet 7	of 8	Attorney Docket Number	31162B

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LAR		ROSENBERG, et al., A Case-Control Study of Oral Contraceptive Use and Invasive Epithelial Ovarian Cancer, 1994, pp. 654-661, Vol. 139, No. 7, USA	
LAR		ROSENBLATT, et al., High-dose and Low-dose Combined Oral Contraceptives: Protection Against Epithelial Ovarian Cancer and the Length of the Protective Effect,	
↓		(continued from above) Eur. J. Cancer, 1992, pp. 1872-1876, Vol. 28A, No. 11, Great Britian	
LAR		ROSSING, et al., Ovarian Tumors in a Cohert of Infertile Women, The New England Journal of Medicine, 1994, pp. 771-776, Vol. 331, No. 12	
LAL		RUDEL, Pharmacology of Contraceptive Steriods, Gynecology and Obstetrics, 1996, pp. 1871-1876, Vol. 6, Chapter 19	
LAR		SCOTT, How to Induce Ovarian Cancer: And How Not To, British Medical Journal, September 29, 1984, pp. 781, 784, Vol. 289, Leeds	
LAR		SPEROFF, et al., Steroid Contraception, Clinical Gynecologic Endocrinology and Infertility, 1989, Chapter 15, 4th Ed., pp. 461-498	
LAR		STANFORD, et al. Epithelial Ovarian Cancer and Combined Oral Contraceptives, International Journal of Epidemiology, 1989, pp. 538-545, Vol. 18, No. 3, Great Britian	
LAR		STANFORD, et al., Depot-Medroxyprogesterone Acetate (DMPA) and Risk of Epithelial Ovarian Cancer, Int. J. Cancer, 1991, pp. 191-195, Vol. 49, Wiley-Liss, Inc.	
LAR		VOGEL, et al. Hormonal Approaches to Breast Cancer Treatment and Prevention: An Overview, Seminars in Oncology, 1996, pp. 2-9, Vol. 23, No. 4, Supp. 9	

Examiner Signature	Date Considered	11 October 2006
--------------------	-----------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/802,273
		Filing Date	03/17/04
		First Named Inventor	Rodriguez
		Art Unit	1614
		Examiner Name	Leslie A. Royds
Sheet 8	of 8	Attorney Docket Number	31162B

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
JML		VOGEL, Update on the current use of hormonal as therapy in advanced breast cancer, use of homonals in advanced breast cancer, Anti-Cancer Drugs, 2003, 14:265-273	
WAL		WINGO, et al., Cancer Statistics 1995, A Cancer Journal for Clinicians, 1995, p. 30, Vol. 45, No. 1	
WAL		WHITTEMORE, Characteristics Relating to Ovarian Cancer Risk: Implications for Prevention and Detection, Gynecologic Oncology, 1994, pp. S15-S19, Vol. 55, USA	
WAL		WHITTEMORE, et al., Characteristics Relating to Ovarian Cancer Risk: Collaborative Analysis of 12 US Case-Control Studies, Am. J. Epidem, 1992, pp. 1212-1220, Vol. 136, No 10	
WAL		WU, et al., Personal and Environmental Characteristics Related to Epithelial Ovarian Cancer, Am. J. Epidem., 1988, pp. 1216-1227, Vol. 128, No. 6, USA	
WAL		YOUNG, et al. Gynecologic Malignancies, Ovarian Cancer, Harrison's Principles of Internal Medicine, 1994, 13th Ed. pp. 1605-608	
WAL		U.S. Patent Application Ser. No. 10/802,427 filed on March 17, 2004 (Inventor: Rodriguez, et al.)	
WAL		Physicians' Desk Reference, 1996, pp. 1871-1876	
WAL		CARLSTROM et al., Gynecologic and Obstetric Investigation, (1978), Vol. 9, No. 6, pp. 304-11 (Medine Abstract Only)	
-	-	-	-

Examiner Signature		Date Considered	11 OCTOBER 2004
--------------------	---	-----------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.